ARTL
Price
$0.96
Change
+$0.01 (+1.05%)
Updated
May 22, 04:43 PM (EDT)
Capitalization
3.13M
76 days until earnings call
FATE
Price
$1.20
Change
+$0.03 (+2.56%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
134.12M
69 days until earnings call
Interact to see
Advertisement

ARTL vs FATE

Header iconARTL vs FATE Comparison
Open Charts ARTL vs FATEBanner chart's image
Artelo Biosciences
Price$0.96
Change+$0.01 (+1.05%)
Volume$1K
Capitalization3.13M
Fate Therapeutics
Price$1.20
Change+$0.03 (+2.56%)
Volume$4.39K
Capitalization134.12M
ARTL vs FATE Comparison Chart
Loading...
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARTL vs. FATE commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARTL is a Hold and FATE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (ARTL: $0.95 vs. FATE: $1.17)
Brand notoriety: ARTL and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARTL: 3% vs. FATE: 76%
Market capitalization -- ARTL: $3.13M vs. FATE: $134.12M
ARTL [@Biotechnology] is valued at $3.13M. FATE’s [@Biotechnology] market capitalization is $134.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARTL’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ARTL’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARTL and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARTL’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 6 bullish TA indicator(s).

  • ARTL’s TA Score: 4 bullish, 4 bearish.
  • FATE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, FATE is a better buy in the short-term than ARTL.

Price Growth

ARTL (@Biotechnology) experienced а -4.25% price change this week, while FATE (@Biotechnology) price change was +21.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.82%. For the same industry, the average monthly price growth was +7.45%, and the average quarterly price growth was -1.67%.

Reported Earning Dates

ARTL is expected to report earnings on Aug 06, 2025.

FATE is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.82% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($134M) has a higher market cap than ARTL($3.13M). ARTL YTD gains are higher at: -10.123 vs. FATE (-29.091). ARTL has higher annual earnings (EBITDA): -10.11M vs. FATE (-176.58M). FATE has more cash in the bank: 279M vs. ARTL (2.34M). ARTL has less debt than FATE: ARTL (104K) vs FATE (85.3M). FATE has higher revenues than ARTL: FATE (13.6M) vs ARTL (0).
ARTLFATEARTL / FATE
Capitalization3.13M134M2%
EBITDA-10.11M-176.58M6%
Gain YTD-10.123-29.09135%
P/E RatioN/AN/A-
Revenue013.6M-
Total Cash2.34M279M1%
Total Debt104K85.3M0%
FUNDAMENTALS RATINGS
ARTL vs FATE: Fundamental Ratings
ARTL
FATE
OUTLOOK RATING
1..100
7713
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
16
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6364
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (16) in the Biotechnology industry is somewhat better than the same rating for ARTL (50) in the null industry. This means that FATE’s stock grew somewhat faster than ARTL’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARTL (100) in the null industry. This means that FATE’s stock grew similarly to ARTL’s over the last 12 months.

FATE's SMR Rating (100) in the Biotechnology industry is in the same range as ARTL (100) in the null industry. This means that FATE’s stock grew similarly to ARTL’s over the last 12 months.

ARTL's Price Growth Rating (63) in the null industry is in the same range as FATE (64) in the Biotechnology industry. This means that ARTL’s stock grew similarly to FATE’s over the last 12 months.

ARTL's P/E Growth Rating (100) in the null industry is in the same range as FATE (100) in the Biotechnology industry. This means that ARTL’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARTLFATE
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 18 days ago
79%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ARTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEYTX27.11N/A
N/A
Fidelity Advisor Asset Manager 85% M
MFWBX17.76N/A
N/A
MFS Global Total Return B
LSAGX22.01N/A
N/A
Loomis Sayles Global Growth A
FSQZX10.49N/A
N/A
Fidelity Advisor Sustainable Intl Eq Z
IOVFX16.48N/A
N/A
GMO International Opportunistic Val I